Wet Age-Related Macular Degeneration Market by Product, by Distribution Channel, by Age Group, by Route of Administration, by End User, by Geography Global Market Size, Share, Development, Growth, and Demand Forecast, 2014-2024

Tuesday, November 12, 2019 Senior Health News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Nov. 11, 2019 /PRNewswire/ --

Wet Age-Related Macular Degeneration (AMD) Market by Product (Lucentis, Eylea, Avastin), by Distribution Channel (Direct, Indirect), by Age Group (Above 80 Years, 6080 Years, 4059 Years), by Route of Administration (Intravitreal, Intravenous), by End User (Hospitals & Clinics, Research & Academic Institutes), by Geography (U.S., Canada, Germany, France, U.K., Italy, Spain, Russia, Sweden, Norway, Belgium, Switzerland, Austria, China, Japan, India, South Korea, Malaysia, Thailand, Australia, Singapore, Brazil, Mexico, Argentina, Colombia, Israel, South Africa, Saudi Arabia) Global Market Size, Share, Development, Growth, and Demand Forecast, 2014-2024

Read the full report: https://www.reportlinker.com/p05775428/?utm_source=PRN

According to the report, the global wet age-related macular degeneration (AMD) market attained a size of $6.9 billion in 2018, and it is expected to reach $10.4 billion by 2024, advancing at a CAGR of 7.1% during the forecast period (2019–2024). The growth of the market is driven by the rising prevalence of AMD, lack of a specific treatment, and increasing aging population. Eylea, Lucentis, and Avastin are the drugs available worldwide for the treatment of wet AMD. Out of these, Eylea is anticipated to dominate the market in 2019–2024. The major factors escalating the demand for this drug in the global wet age-related macular degeneration market are the rising prevalence of AMD. On the basis of route of administration, the market is bifurcated into intravenously and intravitreally given drugs. During the forecast period, the drugs administered through the intravitreal route are predicted to witness the faster growth at a CAGR of 7.2% in the global wet age-related macular degeneration market. In 2018, North America held the largest revenue share, amounting to nearly $3.0 billion, in the global wet age-related macular degeneration market. This is ascribed to the increasing prevalence of wet AMD, rising number of drug approvals, and considerable presence of key players in the country. On a global ground, during the 2019–2024 period, the market is projected to observe the fastest growth with a CAGR of 8.8% in APAC, owing to the surge in the aging population, increase in the prevalence of AMD, and reimbursements offered by the government for treating wet age-related macular degradation in the region. Furthermore, APAC accounts for over one-third of the macular degeneration cases registered across the globe, which is anticipated to further rise during the forecast period. According to United Nations projections, nearly 24.0% of Asians will be of 60 years or above by 2050. Since aged people are more likely to develop AMD, the demand for medication for disease treatment is predicted to substantially rise in the region, resulting in the growth of the wet age-related macular degeneration market. Also, wet AMD treatment is quite expensive, as a result of which the government of countries such as South Korea and Malaysia have introduced some health insurance plans to cover the cost of the treatment to some extent and to lessen the burden of healthcare on people. For instance, under the universal government health insurance plan of South Korea's, during their lifetime, wet AMD patients can get up to 10 injections of ranibizumab. Thus, the increasing government initiatives are boosting the wet age-related macular degeneration market growth in the APAC region. WET AGE-RELATED MACULAR DEGENERATION MARKET SEGMENTATION Market Segmentation by Product • Lucentis • Eylea • Avastin • Others Market Segmentation by Distribution Channel • Direct • Indirect Market Segmentation by Age Group • Above 80 Years • 60–80 Years • 40–59 Years Market Segmentation by Route of Administration • Intravitreal • Intravenous Market Segmentation by End User • Hospitals and Clinics • Research and Academic Institute Market Segmentation by Geography • North America Wet AMD Market - By product - By distribution channel - By age group - By route of administration - By end user - By country – U.S. and Canada • Europe Wet AMD Market - By product - By distribution channel - By age group - By route of administration - By end user - By country – Germany, U.K., France, Italy, Spain, Russia, Sweden, Norway, Belgium, Switzerland, Austria, and Rest of Europe • Asia-Pacific (APAC) Wet AMD Market - By product - By distribution channel - By age group - By route of administration - By end user - By country – Japan, China, India, Australia, Singapore, South Korea, Malaysia, Thailand, and Rest of APAC • Latin America (LATAM) Wet AMD Market - By product - By distribution channel - By age group - By route of administration - By end user - By country – Brazil, Mexico, Argentina, Colombia, and Rest of LATAM • Middle East and Africa (MEA) Wet AMD Market - By product - By distribution channel - By age group - By route of administration - By end user - By country — Israel, South Africa, Saudi Arabia, and Rest of MEARead the full report: https://www.reportlinker.com/p05775428/?utm_source=PRN About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

Cision View original content:http://www.prnewswire.com/news-releases/wet-age-related-macular-degeneration-market-by-product-by-distribution-channel-by-age-group-by-route-of-administration-by-end-user-by-geography-global-market-size-share-development-growth-and-demand-forecast-2014-2024-300955371.html

SOURCE Reportlinker



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search

Premium Membership Benefits

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store